series-c-plus
Stage
3
Investors
About
Juventas (合源生物科技股份有限公司) is a Chinese biopharmaceutical company specializing in cell and gene therapy, focused on developing CAR-T treatments for hematologic malignancies and autoimmune diseases, with its first CAR-T product approved by China's NMPA in 2023.
Explore Juventas's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.